Immunology Investor Event

Dupixent: Prurigo Nodularis Number of patients (thousands) Prevalence(1) 298 Biologic eligible 74 70 27 171 282 107 687 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 US Europe (2) Japan Source: Sanofi analysis (1) 18+ population (2) Germany, France, Italy, Spain & United Kingdom 13 Immunology Investor Event sanofi Patients inadequately controlled by topical corticosteroids

View entire presentation